(Yahoo! Finance) Sept 21, 2017 - AstraZeneca Canada is pleased to announce that the pan-Canadian Oncology Drug Review (pCODR) has provided an overwhelmingly positive clinical recommendation for the reimbursement of Lynparza® (olaparib), a first-of-its-kind treatment for BRCA-mutated ovarian cancer.
(Business Insider) Sept 20, 2017 - Johnson & Johnson continues to face a growing number of product liability claims over the alleged association between its talcum powder products and ovarian cancer. According to an update provided by the U.S. Judicial Panel on Multidistrict Litigation (JPML) on September 15th, there are at least 878...
There are no Ovarian OBR Green articles.